Acorda Therapeutics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Acorda Therapeutics Inc.
S&P 600 Component
Industry Health care
Founded 1995 (1995)[1]
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen (CEO)
Andrew R. Blight
Products Zanaflex
Revenue Increase US$588.22 Million (FY 2017)[2]
Increase US$35.1 Million (FY 2011)[2]
Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Number of employees
328 (February, 2012) [2]

Acorda Therapeutics Inc. is an American biotechnology company based in Ardsley, New York. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.


In September 2014, the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.[4]

In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.[5]

In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.[6]

Corporate governance[edit]

As of June 28, 2018, the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.[7]


Products on the market[edit]

Development pipeline[edit]


External links[edit]